Richard Becker, MD
Staff Affiliate - OtherCards
About
Research
Publications
2025
Endothelial Transcription Factor EB Protects Against Doxorubicin-Induced Endothelial Toxicity and Cardiac Dysfunction.
Du W, Ringer M, Huang W, Desai D, Khandakar G, Tron Esqueda L, Wang C, Guan J, Becker R, Sadayappan S, Fan G, Wang Y, Fan Y. Endothelial Transcription Factor EB Protects Against Doxorubicin-Induced Endothelial Toxicity and Cardiac Dysfunction. Circulation 2025 PMID: 41410033, DOI: 10.1161/circulationaha.124.071774.Peer-Reviewed Original ResearchCardiac microvascular endothelial cellsDOX-induced cardiac dysfunctionMicrovascular endothelial cellsCardiac dysfunctionCardiac functionDoxorubicin treatmentEndothelial cellsProtective effectCardiotoxicity associated with doxorubicinTransgenic miceEC damageCardiotoxicity associated with chemotherapyMeasures of cardiac functionSecretion of proinflammatory cytokinesProinflammatory cytokine releaseTreated with doxorubicinEffective chemotherapeutic drugsIn vivoEC barrier integrityInhibitory effectMouse cardiac microvascular endothelial cellsEC in vitroPerivascular fibrosisEndothelial toxicityCardiovascular toxicityDiscernment and Finding Joy in Medicine: Commentary
Becker R. Discernment and Finding Joy in Medicine: Commentary. The American Journal Of Medicine 2025 PMID: 41177425, DOI: 10.1016/j.amjmed.2025.10.031.Peer-Reviewed Original ResearchA Multiomics Approach to Defining Target‐Organ Injury in Youths With Primary Hypertension: The SHIP AHOY Cohort
Ananthamohan K, Brady T, Arif M, Daniels S, Falkner B, Ferguson M, Flynn J, Hanevold C, Hooper S, Ingelfinger J, Lande M, Martin L, Meyers K, Mitsnefes M, Rosner B, Samuels J, Kuffel G, Zilliox M, Chen Q, Becker R, Urbina E, Sadayappan S. A Multiomics Approach to Defining Target‐Organ Injury in Youths With Primary Hypertension: The SHIP AHOY Cohort. Journal Of The American Heart Association 2025, 14: e037649. PMID: 41147417, PMCID: PMC12684800, DOI: 10.1161/jaha.124.037649.Peer-Reviewed Original ResearchConceptsTarget organ injuryVentricular mass indexBlood pressurePrimary hypertensionMass indexHigh left ventricular mass indexHigh BPLeft ventricular mass indexPeripheral blood mononuclear cellsAngiotensin II treatmentBlood mononuclear cellsCardiovascular disease risk factorsEvidence of molecular changesIndividuals aged <Disease risk factorsHypertrophic responsePediatric populationII treatmentMononuclear cellsAngiotensin IIIntegration of multiomics dataCardiovascular riskChildhood trackCellular hypertrophyVasohibin-1Healthcare in the United States: politics, policy, and potential global impact
Becker R. Healthcare in the United States: politics, policy, and potential global impact. Journal Of Thrombosis And Thrombolysis 2025, 1-11. PMID: 41099930, DOI: 10.1007/s11239-025-03190-3.Peer-Reviewed Original ResearchLife altering eventEvidence-based policyMulti-level collaborationFederal programsHealthcare accessPolicyExecutive actionHealthcare policyUnited StatesGlobal implicationsCommentary advocatesUnited States healthcare policyPoliticsCommentaryAccessCost of careReformAdvocatesResearch collaborationGlobal impactLifeCommitmentCollaborationMedicaidAffordabilityCurrent Perspectives on GLP-1 Agonists in Contemporary Clinical Practice from Science and Mechanistic Foundations To Optimal Translation
Abu-Nejim H, Becker R. Current Perspectives on GLP-1 Agonists in Contemporary Clinical Practice from Science and Mechanistic Foundations To Optimal Translation. Current Atherosclerosis Reports 2025, 27: 99. PMID: 41065947, PMCID: PMC12511252, DOI: 10.1007/s11883-025-01350-7.Peer-Reviewed Original ResearchConceptsGLP-1R agonistsChronic kidney diseaseAtherosclerotic cardiovascular diseaseDiabetes mellitusCombination therapyGLP-1RMuscle mass lossPrevalence of metabolic diseasesClinical trial evidenceGLP-1 agonistsGrowing prevalenceNon-diabetic populationGlobal adult populationContemporary clinical practiceKnowledge of mechanisms of actionEvidence-based useGlycemic control agentsMechanism of actionMetabolic riskMicrovascular dysfunctionPopulation health settingsDrug classesClinical trialsKidney diseaseDiabetes statusImmune checkpoint inhibitors and cardiovascular toxicity: immunology, pathophysiology, diagnosis, and management
Becker R. Immune checkpoint inhibitors and cardiovascular toxicity: immunology, pathophysiology, diagnosis, and management. Journal Of Thrombosis And Thrombolysis 2025, 58: 1021-1044. PMID: 40673965, PMCID: PMC12740968, DOI: 10.1007/s11239-025-03146-7.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsCytotoxic T-lymphocyte antigen (CTLA)-4Discontinuation of immune checkpoint inhibitorsProgrammed cell death (PD)-1Immune checkpoint inhibitor myocarditisImmune-related adverse eventsHigh-dose corticosteroidsSteroid-refractory casesLigand PD-L1Advanced lung cancerCheckpoint inhibitorsCombination immunotherapyPD-L1Immunosuppressive therapyCT angiogramAtrial arrhythmiasImproved survivalCardiac MRICardiovascular toxicityVascular toxicityAdverse eventsAutoimmune biomarkersLung cancerPhysical findingsCardiotoxic effectsCorrection to: C-X-C Ligand 16 Is an Independent Predictor of Cardiovascular Death and Morbidity in Acute Coronary Syndromes
Andersen T, Ueland T, Lakic T, Åkerblom A, Bertilsson M, Aukrust P, Michelsen A, James S, Becker R, Storey R, Wallentin L, Siegbahn A, Kontny F, Investigators F. Correction to: C-X-C Ligand 16 Is an Independent Predictor of Cardiovascular Death and Morbidity in Acute Coronary Syndromes. Arteriosclerosis Thrombosis And Vascular Biology 2025, 45: e336-e336. PMID: 40560990, DOI: 10.1161/atv.0000000000000187.Peer-Reviewed Original ResearchA Multi-Omics Approach to Defining the Target Organ Injury in Youth with Primary Hypertension
Ananthamohan K, Brady T, Arif M, Daniels S, Falkner B, Ferguson M, Flynn J, Hanevold C, Hooper S, Ingelfinger J, Lande M, Martin L, Meyers K, Mitsnefes M, Rosner B, Samuels J, Kuffel G, Zilliox M, Becker R, Urbina E, Sadayappan S. A Multi-Omics Approach to Defining the Target Organ Injury in Youth with Primary Hypertension. Journal Of Molecular And Cellular Cardiology Plus 2025, 12: 100339. DOI: 10.1016/j.jmccpl.2025.100339.Peer-Reviewed Original Research
2024
Bridging the gap: strategies for recognizing and managing post-COVID conditions
Khan M, Becker R. Bridging the gap: strategies for recognizing and managing post-COVID conditions. Frontiers In Medicine 2024, 11: 1395420. PMID: 39635598, PMCID: PMC11615723, DOI: 10.3389/fmed.2024.1395420.Peer-Reviewed Original ResearchQuality of lifePost-COVID conditionsTargeted interventionsPrevalence of chronic conditionsStandardized screening toolPatient-centered approachPrevalence of post-COVID conditionImprove quality of lifeHigh-risk individualsPsychosocial healthHealthcare providersChronic conditionsCardiovascular healthEarly diagnosisImprove qualityScreening toolPeripheral vascular diseaseCommunity leadersComorbid conditionsDevelopment of screening strategiesPersistent symptomsCost-effective screening approachHealthAffected individualsInterventionPATCH (Preferred Attachment Strategy for Optimal Electrocardiograms)-1 Study
Becker R, Harnett B, Wayne D, Mardis R, Meganathan K, Steen D. PATCH (Preferred Attachment Strategy for Optimal Electrocardiograms)-1 Study. Clinical Research In Cardiology 2024, 114: 497-506. PMID: 39527276, DOI: 10.1007/s00392-024-02572-6.Peer-Reviewed Original ResearchStable cardiovascular diseaseAmbulatory clinic visitsAmbulatory clinic settingCardiovascular diseaseS-ECGClinical research coordinatorsClinical indicationsClinic visitsResearch coordinatorsValvular heart diseaseCoronary artery diseaseMedical practiceParticipantsEssential hypertensionClinical settingLead placementAtrial fibrillationHeart diseaseHeart failureTreatment decisionsArtery diseaseST-TElectrocardiographyBaselineHeart rhythm
Academic Achievements & Community Involvement
Clinical Care
Overview
Richard Becker, MD, is a neuoradiologist specializing in radiology and biomedical imaging. He uses medical imaging techniques to diagnose and monitor a wide range of conditions, offering patients insights into their health using technologies such as X-ray, MRI, and CT scans.
At Yale School of Medicine, Dr. Becker is involved in radiology-related research, working on techniques to enhance diagnostic accuracy and patient outcomes.
He received his medical degree from New York Medical College.
Clinical Specialties
Radiology & Biomedical Imaging
Board Certifications
Diagnostic Radiology
- Certification Organization
- AB of Radiology
- Original Certification Date
- 1984
Get In Touch
Contacts
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.